drugset / Trial / NCT06871761

A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes

NCT06871761

Phase 3 Completed 393 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the efficacy and safety of HR17031 injection and insulin glargine, including the changes of efficacy indicators such as HbA1c, fasting blood glucose, body weight and safety indicators such as adverse events and hypoglycemic events.

Timeline

Start
2024-05-08
Primary completion
2025-05-13
Completion
2025-05-13

Drugs

EvaluationDrugModalityDoseRoute
Subject HR17031 Unknown
Comparator insulin glargine Protein / enzyme biologic

Indications

No indication recorded.